REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

[featured_image]
Download is available until [expire_date]
  • Version
  • Download 1
  • File Size 478.80 KB
  • File Count 1
  • Create Date 29/09/2022
  • Last Updated 29/09/2022

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

© 2022, PPHI